Africa institutional business unpredictability
Africa institutional revenue fell 36% YoY due to procurement schedule shifts; management noted this business remains unpredictable.
medium · management_commentary
Ajanta Pharma Limited — Q1 FY25
Ajanta Pharma delivered a strong Q1 FY25 with revenue of INR 1,145 crore (+12% YoY) and EBITDA of INR 330 crore (+22% YoY), driven by branded generics growth of 17%.
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Freight cost headwind of INR 30 crore
Management expects an adverse impact of INR 30 crore in freight costs for FY25 compared to FY24, assuming current rates persist.
medium · analyst_questionUS price erosion in high single digits
US generic price erosion remains stable but at high single digits, which could pressure margins if competition intensifies.
low · analyst_questionEmployee cost one-time charge normalization
Q1 employee costs included a one-time INR 30 crore gratuity policy change; while normalized in subsequent quarters, it highlights potential for future policy-driven cost increases.
low · data_observation